Immune regulatory and anti‐resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.17312 ↗At a glance
Journal article in British Journal of Pharmacology, 2024. Written by Preety Panwar and 3 co-authors. Institution: Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada. Major MEDLINE topics: Arthritis, Rheumatoid, Phenanthrenes. Cited 5 times so far (Crossref); 49 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: CIHR, Collaborative Health Research Projects, Canada Research Chairs.
Abstract (original language)
Background and Purpose Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation and painful joint destruction. Current treatments are helpful in RA remission, but strong immunosuppressive activity and patient resistance are clinical issues. This study explores a dual‐action inhibitor, possessing both anti‐inflammatory and anti‐resorptive properties, as a novel treatment for RA. Experimental Approach Therapeutic efficacy and mechanisms of ectosteric (tanshinone IIA sulfonate [T06]) and active site‐directed (odanacatib [ODN]) inhibitors of cathepsin K (CatK) were evaluated in RA mouse models. Pathology was assessed through biochemical analyses and histopathological examination. Flow cytometry analysis was performed to characterize immune cells. Anti‐inflammatory effects of T06 on nuclear factor kappa beta (NF‐κB) pathway were studied in macrophages. Key Results T06 effectively lowered the number of joint‐resident immune cells, accompanied by significantly reduced production of inflammatory cytokines and collagenolytic proteases. This also included the suppression of Th17 cells and IL‐17, resulting in the reduction of osteoclasts in arthritic joints and amplification of the overall anti‐resorptive effect of T06, which has been attributed to its selective inhibition of the collagenolytic activity of CatK by preventing its oligomerization. The anti‐inflammatory mechanism of T06 was based on blocking the phosphorylation of IκBα in the NF‐κB pathway, resulting in reduced activation and expression of inflammatory cytokines. In contrast, ODN had no effect on inflammation and disease progression and was limited to the inhibition of CatK. Conclusions The combined anti‐resorptive and anti‐inflammatory activities characterize T06 as a novel therapeutic agent for RA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Oral Biological and Medical Sciences, Faculty of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada.
- Centre for Blood Research, University of British Columbia, Vancouver, British Columbia, Canada.
- Department of Pharmaceutical Sciences, Elizabeth City State University, Elizabeth City, North Carolina, USA.
- Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
ORCID profiles: Dieter Brömme
Funding
- CIHR
- Collaborative Health Research Projects
- Canada Research Chairs
- Canadian Institutes of Health Research
Cite
APA
Panwar, P., Andrault, P. M., Saha, D., & Brömme, D. (2024). Immune regulatory and anti‐resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice. British Journal of Pharmacology. https://doi.org/10.1111/bph.17312
Vancouver
Panwar P, Andrault PM, Saha D, Brömme D. Immune regulatory and anti‐resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice. British Journal of Pharmacology. 2024. doi:10.1111/bph.17312
BibTeX
@article{Panwar2024,
author = {Panwar, Preety and Andrault, Pierre Marie and Saha, Dipon and Brömme, Dieter},
title = {Immune regulatory and anti‐resorptive activities of tanshinone IIA sulfonate attenuates rheumatoid arthritis in mice},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.17312}
}
EUVIMED